Citations

Showing 10 of 107861 citations.

Surgical management of the adrenal glands in the multiple endocrine neoplasia type II syndrome
Heerden, Jon A. van, Sizemore, Glen W., Carney, J. Aidan, Grant, Clive S., ReMine, William H., Sheps, Sheldon G.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 8 | Issue: 4 | Pages: 612-619

10.1007/bf01654950 | PMID 6148811 Get It

AbstractDuring a 30‐year period (1951–1981), seventeen patients underwent bilateral adrenalectomy for established adrenal medullary disease with catecholamine excess. Fourteen patients had the MEN IIa syndrome and 3 had the MEN IIb syndrome. There was no major operative morbidity and no operative mortality.One patient died 23 months after initial operation because of metastatic pheochromocytoma. The remaining patients were followed for a mean of 129 months and all were personally interviewed. Three patients had 7 uneventful pregnancies. Twelve patients underwent 23 other surgical procedures requiring general anesthesia during the followup period without any morbidity. Two patients have metastatic pheochromocytoma; 3 have clinical metastatic medullary thyroid carcinoma; 5 patients have high calcitonin values and 6 patients are in excellent health at intervals of 15, 27, 58, 110, 134, and 373 months following resection. The need for adrenal replacement therapy has not caused significant problems in any patient.The results of this study confirm that bilateral total adrenalectomy is a safe modality for the treatment of adrenal medullary disease in this syndrome and that it does not produce significant long‐term morbidity.
Book reviews
Heerden, Jonathan A. van, Goldman, M.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 11 | Issue: 4 | Pages: 553-554

10.1007/bf01655825 Get It

Resection of liver metastases—When is it worthwhile?
Adson, Martin A.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 11 | Issue: 4 | Pages: 511-520

10.1007/bf01655817 | PMID 3630196 Get It

AbstractMost of what has been learned about resection of hepatic metastases comes from the study of colorectal cancer because such lesions are so common. One‐fourth or more of patients who have liver metastases from such lesions have hepatic tumors that can be removed, but only about 25% of these patients will live 5 years or more after such tumors have been removed. When resection so often fails to improve survival, there is a need to know when metastatic lesions should be removed. Study of determinants of prognosis, patterns of failure, and the natural history of the disease have shown that surgical failure is determined by the presence of extrahepatic metastases (even when removed) and limited resective margins. The patient's gender and the locoregional stage of the primary resected lesions influence survival, but not so much as to withhold resective treatment from these less favored groups. Studies of size, site, and number of hepatic metastases removed show therapeutic limitations associated with extremes, but these determinants of prognosis after resection must be studied in better ways. Although, at times, palliation is a reasonable goal, this aspect of resective treatment has not been studied well. When there are no good therapeutic alternatives to resection of hepatic metastases and when risk is low, such palliative operations may be justified. Only with further study will absolute contraindications to surgical therapy be well defined. There is an obvious need for biologic control of cancer.
Invited commentary
Adson, Martin A.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 8 | Issue: 5 | Pages: 756-756

10.1007/bf01655773 Get It

Invited commentary
Adson, Martin A.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 6 | Issue: 2 | Pages: 214-215

10.1007/bf01654693 Get It

Surgical management of malignant islet cell tumors
Grant, Clive S.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 17 | Issue: 4 | Pages: 498-503

10.1007/bf01655109 | PMID 8395750 Get It

AbstractThe surgical management of pancreatic islet cell carcinomas poses a complicated set of questions resulting from their rare occurrence and the difficulty in establishing a diagnosis in early cases or, conversely, the problems inherent in dealing with metastatic disease. However, because their biologic behavior is rather indolent, a real opportunity exists not only for cure but also for meaningful palliation. These goals apply both to the tumor itself and the effects of the hormones they may secrete. The challenge facing the multidisciplinary management team in general, and the surgeon specifically, is to achieve the optimal combination of surgical resection and other treatment options. While the precept of aggressive excision applies to most islet cell carcinomas, it is not universally applicable. In contrast to other islet cell tumors, insulinomas are overwhelmingly benign, and are well treated by enucleation or limited pancreatic resection. Although based on relatively few cases, cytoreductive surgery seems beneficial for malignant insulinomas. Advances that have occurred over the past decade in Zollinger‐Ellison syndrome have markedly altered surgical management. Medication which reliably prevents ulcer formation has permitted the surgical perspective to be redirected from end organ ablation to curative tumor excision. Multicentricity and metastases, however, limit the extent to which cure can actually be achieved. Patients with vasoactive intestinal peptide‐producing tumors and glucagonomas are very rare, and when possible, should undergo tumor resection to correct the severe hormonally caused metabolic derangements. Increasingly recognized are islet cell carcinomas that do not produce clinical syndromes. They may be confused with ductal carcinomas, but when resected, lead to distinctly superior survival rates among patients.
Invited commentary
Sarr, Michael G.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 17 | Issue: 1 | Pages: 132-133

10.1007/bf01655727 Get It

The challenge of the middle mediastinal parathyroid
Curley, Ian R., Wheeler, Malcolm H., Thompson, N W , Grant, Clive S.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 12 | Issue: 6 | Pages: 818-822

10.1007/bf01655485 | PMID 3250132 Get It

AbstractIn most cases of persistent or recurrent hyperparathyroidism (HPT), the pathological parathyroid (PT) will be in the neck or accessible through the cervical approach, and in only a small percentage will median sternotomy be required. We present 3 cases of persistent HPT where the PT tissue was in the middle mediastinum. We acknowledge that this is a rare occurrence and that it cannot be explained adequately by standard embryological teaching. In cases requiring formal mediastinal exploration, the mediastinal exploration is not complete unless the middle mediastinum is carefully explored to exclude ectopic PT tissue.
Invited commentary
Heerden, Jon A. van

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 12 | Issue: 5 | Pages: 689-690

10.1007/bf01655887 Get It

Total pancreatectomy for ductal adenocarcinoma of the pancreas: An update
Heerden, Jon A. van, McIlrath, Donald C., Ilstrup, Duane M., Weiland, Louis H.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 12 | Issue: 5 | Pages: 658-661

10.1007/bf01655878 | PMID 2854327 Get It

AbstractFrom 1951 through December, 1985, a total of 89 patients underwent total pancreatectomy for ductal adenocarcinoma. Of the 89 patients, 54 were male and 35 were female; their average age was 60.0 years. Histologic grading (Broders') demonstrated that 56% of the patients had a grade 2 tumor and 38%, a grade 3 tumor. None of the patients had grade 4 tumors. Peripancreatic lymph nodes were positive in 47% of the patients at the time of resection. Multicentricity was noted in 32.5% of patients. The operative mortality was 10.1%; however, for the patients who had surgery after January, 1980, the operative mortality was 6.2%. At the completion of the study, 78 patients had died and 11 were alive. The principal cause of death was recurrent malignancy. The median duration of survival, including the duration of survival in patients who had operative deaths, was 1.03 years. The influence of sex, tumor grade and size, multicentricity, and nodal status was evaluated multivariately with Cox's proportional hazard model.